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Insulin receptors, as well as IGF-1 receptors and their
postreceptor signaling partners, are distributed through-
out the brain. Insulin acts on these receptors to modulate
peripheral metabolism, including regulation of appetite,
reproductive function, body temperature, white fat mass,
hepatic glucose output, and response to hypoglycemia.
Insulin signaling also modulates neurotransmitter chan-
nel activity, brain cholesterol synthesis, and mitochon-
drial function. Disruption of insulin action in the brain leads
to impairment of neuronal function and synaptogenesis. In
addition, insulin signaling modulates phosphorylation of
tau protein, an early component in the development of
Alzheimer disease. Thus, alterations in insulin action in the
brain can contribute to metabolic syndrome, and the
development of mood disorders and neurodegenerative
diseases.
Since the discovery of insulin over 90 years ago, much
progress has been made in unraveling the mechanism of
insulin action and its physiological functions, especially in
classic target tissues, such as liver, muscle, and fat. Over the
past decade, work from our laboratory and others has shown
that insulin action is also important in tissues previously
thought to be insulin insensitive, including the brain, b-cell,
and vascular endothelium (1). In this review, we will describe
recent discoveries regarding insulin action in the brain, and
illustrate how this can affect both the brain and peripheral
metabolism. In addition, we will explore how insulin action
in the brain can affect brain function and the pathogenesis
of neurodegenerative diseases.
INSULIN SIGNALING MACHINERY IN THE BRAIN
Insulin and the closely related IGF-1 and IGF-2 mediate
their biological effects through two highly related tyrosine
kinase receptors—the insulin receptor (IR) and the IGF-1
receptor (IGF-1R) (2). Both IRs and IGF-1Rs are expressed
throughout the brain. Previous studies using in situ hy-
bridization and immunohistochemistry have demon-
strated differential distribution throughout the brain. In
the mouse, the highest expression of the IR is in the
olfactory bulb, followed by the cortex, hippocampus, hy-
pothalamus, and cerebellum, with relatively low levels in
the striatum, thalamus, midbrain, and brainstem (3–5). In
contrast, the IGF-1R has the highest expression in the
cortex, hippocampus, and thalamus, whereas moderate
expression is observed in the olfactory bulb, hypothala-
mus, and cerebellum, with the lowest expression in the
striatum, midbrain, and brainstem (3). To directly com-
pare the expression of these receptors across the brain
and to each other, we assessed transcript copy numbers
found in areas of dissected brain using quantitative real-
time PCR against standard curves from plasmids contain-
ing IR and IGF-1R cDNAs (Fig. 1). IR mRNA levels ranged
from 250 copies/ng in the raphe nucleus to ;475 copies
of IRs in the cerebellum, whereas the IGF-1R mRNA copy
number ranged from ;600 copies in the hypothalamus to
almost 1,000 in the cerebellum (i.e., about twice the num-
ber of IRs) (Fig. 1). How this relates to protein levels of
these two receptors, and how expression varies among the
individual cells and cell types in each region of the brain
remains to be determined.
Most importantly, these two receptors have different
physiological functions in the brain, as shown by genetic
knockout in mice. Mice with genetic deletion of IRs in the
brain (i.e., neuron-speciﬁc IR knockout [NIRKO]) have
normal brain size and development, but exhibit metabolic
phenotypes, including mild obesity and insulin resistance
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(6). Knockout of IGF-1R in the brain, on the other hand,
results in reduced brain size, generalized growth retarda-
tion, and behavioral changes (7). Interestingly, heterozy-
gous deletion of IGF-1R in the brain does not affect brain
growth, but results in a complex phenotype that includes
reduced body weight, but increased fat mass, impaired glu-
cose tolerance, and extended life span (7).
Differences in gel mobility and biochemical studies of
IR and IGF-1R subunits isolated from the brain indicate
differences in glycosylation of these receptors from those in
peripheral tissue (8,9). Also, in contrast to the peripheral
tissues, which express predominantly the B isoform (+exon
11) of the IR, the brain expresses predominantly the A iso-
form (2exon 11), which has a higher afﬁnity for IGF-2 (2).
As in peripheral tissues, IRs and IGF-1Rs can heterodimerize,
and in rabbit brain approximately half of IGF-1Rs and the
majority of IRs appear to exist as heterodimers (10). This is
thought to favor a response to IGF-1 over insulin. Thus, it is
likely that in the brain, insulin and the IGFs exhibit consider-
able cross-talk in signaling and biological effects.
Both IR and IGF-1R use similar intracellular signaling
machinery, and all of the major components present in
peripheral tissue are present in the brain. Among the IR
substrates (IRSs), IRS-2 mRNA is most abundant, ranging
from 5,000 copies/ng in the prefrontal cortex to 13,000
copies/ng in the cerebellum, compared with IRS-1, which
ranges from 1,800 copies/ng in the raphe nucleus to 5,300
copies/ng of reverse-transcribed RNA in the cerebellum
(Fig. 1). Interestingly, both IRS-1 and IRS-2 are expressed
at much higher levels than IR or IGF-R, at least at the
mRNA level. Again, it will be important to understand the
speciﬁc cellular distribution of these proteins. Recently, it
has been shown that IRS-4, which is mainly expressed in
embryonic development, is also expressed in the brains of
adult mice, especially the hypothalamus (11,12). Numer-
ous studies have shown that IRS-1 and IRS-2 have both
overlapping and distinct functions. At the whole-body
level, IRS-1 appears to be critical for growth, since IRS-
1-null mice are runted (13). However, brain size remains
near normal, resulting in an increased brain-to-body ratio.
On the other hand, IRS-2 is important for brain develop-
ment, and IRS-2-null mice exhibit a reduced brain-to-body
ratio (14). Despite this, IRS-2-null mice are long lived
(15), consistent with a role of central insulin/IGF signal-
ing in control of life span in mammals. IRS-4 seems to be
at least partially functionally redundant to IRS-1 and
IRS-2 and may synergistically cooperate with IRS-2 in the
hypothalamus to control food intake, energy expenditure,
and glucose metabolism (16).
One of the major downstream pathways of IRS
proteins is the PI3K /Akt cascade (17). This, in turn, tar-
gets multiple downstream pathways, including mTORC1,
GSK3b, and the FoxO family of transcription factors
(3). Many of these pathways have been shown to play
pivotal roles in normal brain function. For instance,
mTORC1-mediated protein synthesis is important for
synaptic plasticity (18) and the regulation of autophagy,
a major mechanism to degrade misfolded proteins and
damaged organelles in neurons (19). Dysregulation of
mTORC1-dependent autophagy in neurons results in neu-
ronal cell death and the onset of neurodegenerative dis-
eases. GSK3b regulates multiple aspects of neuronal
functioning, including neural progenitor cell proliferation,
neuronal polarity, and neuroplasticity (20). GSK3b can also
phosphorylate tau protein, a process involved in the path-
ogenesis of Alzheimer disease (AD). Insulin stimulates
Figure 1—Expression of IR, IGF-1R, IRS-1, and IRS-2 in the brain. The expressions of IR, IGF-1R, IRS-1, and IRS-2 were determined by
quantitative real-time PCR of brain regions dissected from male C57BL/6 mice. Serial dilutions of plasmids encoding the cDNA sequences
of corresponding genes were used for the standard curves. Data are expressed as the copy number per nanograms of RNA transcribed.
Cb, cerebellum; CP, caudate putamen; Hpc, hippocampus; Hy, hypothalamus; NA, nucleus accumbens; NST, nucleus tractus solitaries;
PFC, prefrontal cortex; RN, raphe nucleus; VTA, ventral tegmental area.
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phosphorylation of GSK3b, and this reduces its enzymatic
activity. Brain-speciﬁc knockout of IR or IRS-2 results in
decreased GSK3b activity and increased tau phosphoryla-
tion (14,21) (see below). FoxOs play diverse and impor-
tant roles in the central nervous system (CNS), including
controlling energy homeostasis and leptin sensitivity, as
well as locomotor activity (22,23).
Insulin/IGF-1 signaling also activates the Grb2-SOS-Ras-
MAPK cascade, which plays a direct role in cell proliferation,
differentiation, gene expression, and cytoskeletal reorgani-
zation. This pathway also contributes to the normal function
and survival of neuronal cells (24). Inhibition of MAPK
has also been shown to block insulin and leptin stimula-
tion of hypothalamic neuroprogenitor cells (25).
Taken together, these studies demonstrate that IR and
IGF-R, as well as their common downstream pathways, are
present in the brain. More importantly, these pathways
function as regulators of neurogenesis, brain function, and
whole-body energy balance and metabolism.
HOW DOES INSULIN GET TO THE BRAIN?
Although the presence of insulin in the cerebrospinal ﬂuid
(CSF) is well documented, the origin of “brain” insulin is
controversial. Insulin levels in the CSF are ;25% of those
in the blood and increase proportionally after meals or
with peripheral insulin infusion, suggesting that a fraction
of plasma insulin is able to cross the blood-brain barrier
via a saturable transport process, possibly the IR on vascu-
lar endothelium (26,27). It also appears that there are
regions of the brain, such as the hypothalamus, that lack
an effective barrier, allowing insulin more ready access.
Indeed, studies (28) have shown rapid activation of insulin
signaling in these regions after peripheral insulin injection.
Whether insulin can also be locally synthesized in the
brain, however, remains under debate. In lower organisms,
like Caenorhabditis elegans and Drosophila, insulin-like pep-
tides not only are produced in neurons, but neurons are
the primary source of these peptides (3). Older experi-
ments using a radioimmunoassay on extracts of whole
rat brains show signiﬁcantly higher insulin concentrations
than plasma (29); however, these have not been supported
by more recent studies. On the other hand, some in vitro
experiments (30) have shown that insulin can be synthe-
sized and secreted by rabbit CNS neuronal cells in culture,
and studies (31–34) using the mouse or rat insulin 2 pro-
moter to drive transgenic gene expression have also shown
the expression of reporter genes in the hypothalamus. Nev-
ertheless, no evidence has deﬁnitively demonstrated that
insulin synthesis in the brain in rodents or humans is
physiologically important, although there still remains
a possibility that local insulin production is important for
speciﬁc regional effects.
INSULIN ACTION ON NEURONAL FUNCTION AND
SYNAPTIC PLASTICITY
The best-studied effects of insulin signaling in the brain
are those regarding food intake and energy expenditure.
As early as 1979, Woods et al. (35) showed that intracere-
broventricular infusion of insulin in baboons could markedly
decrease food intake and body weight gain. Insulin admin-
istration into the third ventricle in rodents has been shown
to decrease food intake by decreasing expression of the
orexigenic neuropeptides neuropeptide Y (NPY) and Agouti-
related peptide (AgRP), and by increasing the expression of
anorexigenic neuropeptides proopiomelanocortin (POMC)
and cocaine- and amphetamine-regulated transcript (CaRT)
in the arcuate nucleus, which together result in increased
activity of a-melanocyte-stimulating hormone in neurons
in the paraventricular nucleus (Fig. 2A) (36). Conversely,
in the hypothalamus of insulin-deﬁcient streptozotocin
(STZ)-treated mice, there is an increase in NPY and AgRP
accompanied by a decrease in POMC and CaRT (Fig. 2B).
As a result, brain-speciﬁc deletion of IR in mice leads to
increased food intake and mild obesity (6). This anorexi-
genic effect of insulin is, at least in part, a result of PI3K-
dependent activation of ATP-dependent potassium channels
in hypothalamic neurons, which hyperpolarize and inactivate
the orexigenic AgRP neurons (37).
A number of lines of evidence have shown that central
insulin action is also associated with alterations in
cognitive function in the brain. Patients with both type 1
and type 2 diabetes are at higher risk for behavioral
changes and accelerated cognitive decline with aging, and
patients with type 2 diabetes have a higher rate and more
rapid progression of AD (38). In humans with either type 1
or type 2 diabetes, imaging studies have demonstrated
smaller hippocampi, as well as changes in the functional
connectivity between regions of the brain (39–43). Multi-
ple rodent models of diabetes have memory impairment
(44,45), whereas central insulin infusion in rats signiﬁ-
cantly improves memory tasks, including performance in
the passive avoidance task and Morris water maze (46,47).
All of these point to the possible role of IR in neuronal
signal transmission.
The effects of insulin differ in different neuronal
populations. Insulin reduces the activity of AgRP neurons,
whereas it increases the activity of dopamine neurons
(37,48). Insulin also regulates the transmission of
N-methyl-D-aspartate (NMDA) receptors in hippocampal
neurons through the tyrosine phosphorylation of speciﬁc
subunits of the NMDA receptors NR2A and NR2B (49),
and appears to trigger the membrane recruitment of
NMDA receptors into excitatory synapses (50). As a result,
insulin-dependent enhancement of NMDA receptor activ-
ity in the postsynaptic terminal contributes to the develop-
ment of long-term potentiation in the hippocampus (51),
an important step in learning and memory. Insulin has also
been shown to regulate a-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors in the hippocampus
and cerebellum, triggering the clathrin-dependent endocy-
tosis of AMPA receptors via the PI3K-PKC pathway
(52,53). In the hippocampal CA1 neurons, this down-
regulation of AMPA receptor activity in excitatory syn-
aptic terminals plays a role in insulin-induced long-term
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depression, which is generally considered essential for
both memory consolidation and memory ﬂexibility (54).
IRs also have been shown to regulate type A g-aminobutyric
acid (GABA) receptor activity through both membrane
recruitment and protein synthesis in hippocampal neu-
rons, thereby regulating the activity of inhibitory syn-
apses (55). Furthermore, insulin can regulate structural
plasticity in the brain, including synapse number, den-
dritic plasticity, and visual circuit function (56), and can
induce the expression of PSD95, a scaffold protein that is
essential for the formation of the postsynaptic junction
(57). All of these studies provide molecular mechanisms to
support the positive effects of insulin on brain function
and behavior.
IR expression and action in the CNS is not restricted
to neurons, but may also occur in glial cells (58). Thus
far, this speciﬁc aspect of central insulin action has re-
ceived little attention; however, it is important to keep
in mind that in the NIRKO mouse, which is the best
studied model of genetically induced CNS insulin resis-
tance, IRs are ablated in both neurons and glial cells.
Insulin has been shown to stimulate proliferation, glu-
tamate receptor expression, and cholesterol biosynthetic
genes in glial cells, indicating that these cells are insulin
sensitive (59–61). Glial cells, especially astrocytes, are
considered the major energy suppliers for neurons (62).
Moreover, astrocytes play key roles in regulating the
homeostasis of the synaptic junction microenviron-
ment, as well as inﬂammation (63,64). Future studies
will need to determine the potentially important roles
of IR and IGF-1R on glial cells, including astrocytes,
oligodendrocytes, and microglia.
CNS INSULIN SIGNALING AFFECTS PERIPHERAL
TISSUES
Experiments manipulating the levels of insulin or IR in
the brain have demonstrated a role of central insulin
signaling in the regulation of several peripheral tissues
(Fig. 3). For example, insulin suppression of glucose pro-
duction in the liver (gluconeogenesis) is regulated by IRs
in both the liver and brain, such that genetic inactivation
Figure 2—Insulin regulates orexigenic and anorexigenic peptides
and body temperature. A: Insulin regulates appetite through the
hypothalamus. In the arcuate nucleus (ARC) of the hypothalamus,
insulin binds to IRs on POMC neurons to increase the expression of
anorexigenic peptides, POMC, and CaRT, which results in in-
creased activity of a-melanocyte–stimulating hormone (a-MSH)
on melanin-concentrating hormone (MCH) neurons in the paraven-
tricular nucleus (PVN). Conversely, insulin acts on AgRP neurons to
inhibit the expression of orexigenic peptides AgRP and NPY. In
addition, upon insulin binding, IR activates PI3K, triggering ATP-
dependent potassium (KATP) channels, K
+ efﬂux, and hyperpolar-
ization of AgRP neurons. This results in the attenuation of the
inhibitory effect of AgRP neurons on both MCH and POMC neu-
rons. In parallel, insulin and leptin act to decrease food intake. B:
Transcription of the orexigenic peptides AgRP and NPY is in-
creased, and transcription of the anorexigenic peptides POMC and
CaRT is decreased in the hypothalami of STZ-treated mice com-
pared with controls, as determined by microarray analysis on iso-
lated hypothalami of C57BL/6 mice 10 days after treatment with
vehicle or STZ to induce diabetes. Data are expressed as the per-
centage change over vehicle-treated mice. P < 0.01 for all genes.
C: Brain IR knockout (NIRKO) mice show a signiﬁcant drop in body
temperature compared with controls when exposed to 4°C cold
stress, indicating a defect in thermogenesis. Experiments were
performed on 17-month-old female mice. ***P < 0.001.
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of IRs in either of these tissues causes a loss of insulin
suppression of hepatic glucose production (65,66). In the
brain, this appears to involve IRs speciﬁcally in the AgRP
neurons (37,65,67). Insulin action at the brain acts on
gluconeogenesis also in part through stimulation of tyro-
sine phosphorylation of STAT3 in the liver (63). This
results in an increase in hepatic interleukin-6 production,
which inhibits hepatic glucose production, contributing
further to the brain-liver control of gluconeogenesis. Con-
versely, CNS injection of insulin increases hepatic insulin
sensitivity, and this occurs through central pathways in-
volving PI3K and ATP-dependent potassium channels
(66). Additionally, administration of insulin into the
CNS promotes lipogenesis and peripheral fat accumula-
tion (68). Insulin action in the brain also modulates the
counter-regulatory response to hypoglycemia (69). Con-
sistent with this, mice with a knockout of IR in the brain
display a blunted sympathoadrenal response to hypoglycemia
(67,70), showing that central insulin signaling directly
alters glucose sensing in hypothalamic neurons. Central
insulin does not, however, appear to affect glucose uptake
in skeletal muscle or adipose tissue.
Insulin in the brain also impacts the control of body
temperature. Thus, the injection of insulin or IGF-1 into
the preoptic area can activate brown adipose tissue and
induce hyperthermia. This effect is lost in the NIRKO
mouse, indicating that it is mediated by IR (71). Consis-
tent with this, NIRKO mice have an impaired response to
cold exposure (Fig. 2C). Intranasal administration of in-
sulin has also been shown to enhance postprandial ther-
mogenesis in humans (72). Interestingly, sympathetic
nervous system outﬂow from the brain to brown adipose
tissue stems from very insulin-sensitive regions of the
hypothalamus (73). In view of the recent ﬁnding of active
brown fat in humans and reduced activity of this fat in
obese individuals, it will be important to determine the
role of brain insulin resistance in this response.
Insulin resistance is associated with impaired female
reproduction and is a central feature in the pathogenesis
of polycystic ovary syndrome. In addition, central obesity
is associated with both insulin resistance and menstrual
disorders, indicating that metabolic disorders may affect
fertility. The best evidence that insulin in the brain has
a direct effect on reproductive function comes from
NIRKO mice, in which both sexes display hypothalamic
hypogonadism, with reduced fertility due to hypothalamic
dysregulation of luteinizing hormone, which can be
corrected by the injection of gonadotropin-releasing
hormone and follicle-stimulating hormone (6). Mice lack-
ing IRS-2 also have reduced serum levels of luteinizing
hormone and show reduced fertility (74). Female mice
with knockout of IR in gonadotropin-secreting pituitary
cells, on the other hand, display a paradoxical increase in
fertility in the context of obesity (75), highlighting the
complexity of insulin action at different levels of the CNS
on the reproductive axis.
INSULIN ACTION ON BRAIN AND
NEURODEGENERATIVE DISEASES
Over the past decade, a number of studies (76,77) have
shown an association between AD and decreased insulin
signaling in the CNS, suggesting that reduced insulin
Figure 3—Effects of insulin signaling in the brain on central and peripheral function. Brain insulin resistance results in increased food intake,
hypothalamic hypogonadism, hypothermia, decreased white fat mass, increased hepatic glucose output, impaired response to hypogly-
cemia, and impaired neural function. ARC, arcuate nucleus; DMX, dorsal motor vagal nucleus; NTS, nucleus of the solitary tract.
2236 Insulin in Metabolism and Brain Function Diabetes Volume 63, July 2014
action might play a role in the pathogenesis of this dis-
ease. Patients with AD exhibit reduced expression and
activation of IR, IGF-1R, and IRS-1 proteins in the brain,
in particular in the hippocampus and hypothalamus, as
well as increased serine phosphorylation in IRS-1, which
is generally regarded as inhibitory (78,79). They also have
lower insulin concentrations in the CSF, but higher insulin
concentrations in plasma, suggesting reduced insulin action
in the CNS. In line with this possibility, a small clinical trial
of intranasal insulin administration to individuals with AD
decreased the rates of cognitive decline (80).
Whether insulin resistance is a cause or consequence of
AD is still not clear; however, insulin action has been
shown to play a role in several important parts of the
progressive pathogenesis of AD. Aggregated amyloid-b
(Ab) ﬁbrils and hyperphosphorylation of tau protein caus-
ing amyloid plaques and helical neuroﬁbrillary tangles are
hallmarks of AD, and these can be ameliorated by insulin
signaling (81). Mechanistically, insulin and IGF-1 treat-
ment have been shown to decrease the intracellular Ab
burden by increasing the trafﬁcking and clearance of Ab
via the MAPK pathway, which alleviate gliosis and cogni-
tive deﬁcits in a mouse model of AD (82–84).
We have shown that deletion of brain IRs (NIRKO)
results in increased phosphorylation of tau protein, one of
the major components of pathologic neuroﬁbrillary tan-
gles (21). As noted above, tau hyperphosphorylation
occurs secondary to a decrease in GSK3b phosphoryla-
tion, which results in increased GSK3b activity. Despite
the increased phosphorylation of tau, NIRKO mice do not
develop memory disorders. This may be due to opposing
effects at other levels in the multistage pathogenesis of
this disease (Fig. 4). Moreover, knockout of IR has been
shown to reduce amyloid burden in a mouse model of AD,
and knockout of IRS-2 reduces mortality in a mouse
model of AD (85,86). On the other hand, the treatment
of mice and rats with drugs that stimulate insulin secre-
tion, such as exendin-4 or intranasal insulin, has been
shown to reduce neurological pathologies in AD mice
(87–89). Synaptic loss, a phenotype of AD patients, can
also be rescued with insulin treatment of cultured neurons
(90). Insulin and Ab are both substrates of insulin-degrading
enzyme, and it has been suggested that hyperinsulinemia
inhibits the degradation of Ab by competitively blocking
insulin-degrading enzyme (91). Finally, the administration
of intranasal insulin in humans, which allows for high
doses of insulin to be delivered to the brain, can result
in improved cognitive function in certain groups of AD
patients, while suppressing lipolysis in healthy adults
(80,92). The cognitive response in AD patients seems to
be dependent on sex, insulin dose, and apolipoprotein
(Apo)Ee4 status, underscoring the complexity of insulin
action in the brain.
Brain insulin resistance is also associated with Parkinson
disease (PD). In some studies, patients with type 2 diabetes
exhibit an almost twofold increased risk of PD compared
with control subjects (93). PD patients also show reduced
expression of IRs, IGF-1Rs, and their endogenous ligands in
various brain regions, along with increased numbers of
markers of insulin resistance, inﬂammation, and mito-
chondrial dysfunction (94). Type 2 diabetes mouse models
express more a-synuclein, the protein involved in Lewy
body formation in PD patients, and exhibit increased sus-
ceptibility to toxin-induced dopaminergic loss (95). Mutant
a-synuclein, which is present in one form of genetic PD,
can inhibit AKT activation, indicating that this pathology
Figure 4—Insulin resistance in the brain inﬂuences neurological function through multiple pathways. Impaired insulin signaling in the brain
leads to decreased SREBP-2/SCAP-dependent cholesterol synthesis, altered synaptic plasticity, mitochondrial dysfunction, and increased
tau phosphorylation, all of which may contribute downstream to impaired neurological functioning, including AD and mood disorders.
AMPA-R, AMPA receptor; NMDA-R, NMDA receptor.
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can also inﬂuence insulin sensitivity (96). Thus, it is in-
triguing to hypothesize that the increase in AD and PD
pathogenesis seen later in life is driven, in part, by the
age-related decline observed in IGF-1 and insulin concen-
trations and receptor expression.
ALTERATIONS IN CHOLESTEROL METABOLISM
AND MITOCHONDRIA IN DIABETES AND AD
We and others have shown that another possible link
between diabetes and AD is altered cholesterol metabo-
lism. ApoE is the major apolipoprotein and the principal
carrier of cholesterol in the brain. The genetic variant
ApoEe4 is the most common risk factor for late-onset AD,
but the mechanism behind this observation remains
largely unknown (97). In vitro experiments coculturing
astrocytes and neurons suggest that cholesterol is synthe-
sized in astrocytes, packaged into ApoE particles, and
secreted to be taken up by neurons and incorporated
into membranes to augment synaptogenesis and vesicle
formation (98). We have shown that diabetic mice, in-
cluding models of both type 1 and type 2 diabetes, have
decreased cholesterol biosynthesis in the brain due to de-
creased expression and/or function of SREBP-2, the major
regulator of cholesterologenic gene transcription (61).
These mice also have decreased levels of SREBP cleavage-
activating protein (SCAP), a sterol-sensing molecule, which
contributes to altered processing of immature SREBP-2 to
its mature form, leading to a further defect in cholesterol
synthesis (61,99). The decrease in cholesterol synthesis that
occurs in STZ diabetic mice can be reversed by the admin-
istration of insulin into the third ventricle at levels that do
not affect blood glucose levels or peripheral metabolism,
indicating that these changes in cholesterol metabolism
are due to a direct action of insulin on the brain. Interest-
ingly, we found that primary cultures of both neurons and
glia express all of the enzymes of cholesterol synthesis and
that both can be stimulated by insulin in vitro, implicating
both neurons and glia in the maintenance of normal cho-
lesterol levels in the brain.
The brain is a very cholesterol-rich organ with choles-
terol densely packed into the cell membranes, contributing
to membrane ﬂuidity, vesicle formation, and synapto-
genesis (100). To understand the consequences of modest
decreases in cholesterol synthesis similar to those seen in
diabetic mouse brains without the other accompanying
metabolic changes associated with diabetes, we studied
mice with a heterozygous deletion in the brain of SCAP,
and performed a knockdown of SREBP-2 in isolated neu-
rons in vitro. We found that mice with a 50% reduction in
SCAP had reductions in SREBP-2 and in vivo cholesterol
synthesis similar to those seen in diabetic mice (99). This
resulted in defects in synaptic transmission, including
alterations in long-term potentiation, implying a memory
defect. On behavioral testing, SCAP knockout mice also
demonstrated impaired learning and abnormal stress
responses (Fig. 5), further implicating insulin regulation
of brain cholesterol metabolism as another link between
diabetes and AD. Importantly, the knockdown of SREBP-2
in isolated neurons in culture also resulted in a decrease
in the formation of synapses and synaptic vesicles (Fig.
5) (61). Thus, insulin regulation of cholesterol synthesis
may be an important component of the effects of diabe-
tes on altered brain and nerve function.
Mitochondrial stress has also been proposed as both
a contributor to and consequence of the pathologies seen
in AD (101). Recent data demonstrate that in the brains
of obese diabetic mice and diabetic humans there is de-
creased expression of the mitochondrial chaperone heat
shock protein 60 (Hsp60) (28). In mice, this appears to be
due, at least in part, to a lack of proper leptin action in the
hypothalamus. Mice with a heterozygous deletion of
Hsp60 have increased mitochondrial dysfunction, which
is accompanied by insulin resistance in the hypothalamus.
Further, mitochondrial dysfunction induced by the knock-
out of mitofusin 1 or 2 in AgRP neurons results in impaired
neuronal ﬁring in mice exposed to a high-fat diet (102).
Taken together, these data indicate that insulin action
in the brain can alter neuronal and glial function in
multiple ways and also can modify the pathogenesis of
neurodegenerative diseases like AD at multiple steps (Fig.
4). Coupled with a preliminary study (80) showing that
intranasal insulin application may reduce cognitive de-
cline in AD patients, the insulin signaling pathway is an
important target for future AD research.
INSULIN IN THE BRAIN AND MOOD DISORDERS
Multiple studies have shown an association between de-
pression and both type 1 and type 2 diabetes beyond what
is associated with living with a chronic disease (103). The
mechanisms by which diabetes can inﬂuence depression re-
main elusive but may relate to effects of insulin on neuro-
transmission, as well as indirect effects linked to insulin
resistance, such as inﬂammation and increased cytokine
production (103). Several brain areas have been implicated
in the pathogenesis of mood disorders, including the pre-
frontal cortex, nucleus accumbens, striatum, amygdala, and
raphe nucleus, all of which are areas of the brain that ex-
press IR (Fig. 1). Insulin signaling has been shown to mod-
ulate the dopaminergic and serotonergic systems, which are
pathways that play a pivotal role in depression (104,105).
For example, central insulin administration can increase
dopamine transporter protein expression in rats via
a PI3K-dependent pathway (106–108), thereby ﬁne-tuning
dopamine signaling. Additionally, the ablation of IR in cat-
echolaminergic neurons attenuates insulin-induced excit-
ability in dopaminergic neurons, indicating that insulin
might modulate their neuronal activity, affecting depression
(106,107,109). On the other hand, insulin has also been
shown to increase serotonin levels in the brain, suggesting
a beneﬁcial effect of insulin signaling on the dopamine and
serotonin signaling cascade, and thus possibly on mood
(110). Both type 1 and type 2 diabetes animal models ex-
hibit depressive-like behavior (111,112), which can be ame-
liorated by treatment with insulin or insulin sensitizers
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Figure 5—SCAP and SREBP-2 are important for synapse formation, nerve ﬁring, and memory tasks. Top: SREBP-2 was silenced with
a green ﬂuorescent protein (GFP)-lentiviral construct (Lenti-shSREBP-2 [short hairpin SREBP-2]) in primary cultured mouse hippocampal
cells. The PSD95 marker is represented in red, and the neuronal marker MAP2 is shown in blue. Adapted from Suzuki et al. (61). Middle:
Mice with heterozygous deletion of SCAP show a decrease in spontaneous neuronal activity, as determined by basal recordings of
miniature excitatory postsynaptic current in area CA1 neurons (adapted from Suzuki et al. [99]). Bottom: Impaired memory task perfor-
mance. For the novel object recognition test, mice were trained for 5 min with two identical objects. One hour later, they were placed back
in the same cage with one familiar and one novel object, and were monitored by video for 5 min. Mice with a heterozygous deletion of SCAP
in the brain showed no exploratory preference for the novel object. Adapted from Suzuki et al. (99). CTR, control.
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(113,114). At a mechanistic level, insulin decreases the ac-
tivity of monoamine oxidase, the enzyme responsible for
degrading serotonin and dopamine, thereby increasing the
activity of those systems (113). Ongoing studies in our
laboratory reveal that NIRKO mice exhibit altered behavior,
such as an increase in anxiety and depression-like behaviors
with aging, indicating that central insulin signaling can af-
fect complex behaviors and mood (A. Kleinridders, unpub-
lished observations).
INSULIN ACTION IN THE BRAIN AND LONGEVITY
The effect of insulin signaling on life span may also
involve the brain. This was ﬁrst shown in C. elegans where
hypofunctional mutations in daf-2 (the homolog of mam-
malian IRs and IGF-1Rs) were shown to increase longevity
by up to 250%. Several other alterations in the insulin/
IGF-1 pathway, such as overexpression of FoxO1 and in-
activation of Akt, support the initial observation that re-
duced insulin/IGF-1 signaling in eukaryotes prolongs life
span (115,116). A similar beneﬁcial effect of reduced in-
sulin/IGF-1 signaling on longevity is found in ﬂies (117).
In both worms and ﬂies, these effects can be cell non-
autonomous, and have been shown to involve loss of in-
sulin signaling in neurons, as well as in adipose tissue in
the ﬂy and the gut in worms (116).
Studies in mammals suggest that both IR and IGF-1R
may have effects on longevity, but the relationship is
complex, since deletion or hypofunction of either receptor
profoundly affects growth and physiology, making it
difﬁcult to elucidate any direct effect on aging. The most
direct evidence that insulin and/or IGF-1 signaling in the
brain can extend life span comes from studies of mice with
knockout of IRS-2 in the brain and whole-body IRS-2
heterozygous mice on both a wild-type and Huntington
disease background (15,118), both of which show an in-
creased life span, conﬁrming that in mammals decreased
insulin/IGF-1 signaling can be beneﬁcial for survival. How-
ever, brain-speciﬁc knockouts of the IR do not appear to
have increased longevity, but this may be the result of
other defects that negatively affect life span. However,
fat-speciﬁc IR knockout mice (119) and whole-body IGF-
1R heterozygous mice (120) both have an extended median
and maximum life span (;15–20%). Increased levels of
Hsp60, a known regulator of central insulin action (121),
in the brain are seen in long-lived animal species, further
suggesting a role for central insulin signaling and longevity
(122). Also, genetic variation within the FoxO3a gene,
a transcription factor downstream of the IR, is associated
with human longevity (123), but how this relates to central
insulin signaling is unknown. Further studies will be re-
quired to understand the full role of insulin versus IGF-1
signaling at the level of the brain in longevity.
CONCLUSIONS AND FUTURE PERSPECTIVES
Insulin is a key homeostatic factor in the brain, acting
through both the IR and IGF-1R to maintain the health of
the brain and to inﬂuence systemic metabolism. Current
data demonstrate that insulin signaling in the brain is vital
in the ﬁne-tuning of brain activity. Through direct neuronal
effects, and regulation of cholesterol synthesis, mitochon-
drial function, tau phosphorylation, and Ab processing,
defects in insulin signaling provide a link between diabetes
and CNS disorders. Recent work (124,125) also suggests
that insulin may play a role in the severity of strokes, further
expanding the therapeutic potential for insulin. This also
raises important questions as to how to treat these abnor-
malities and the role of intranasal insulin or alternative
routes of administration for increasing central insulin action
as a component in the management of AD and other neuro-
cognitive disorders. The effects of insulin action on brain
lipid metabolism, not only cholesterol as described here, but
free fatty acids and triglycerides as evidenced by the effects
of brain lipoprotein lipase knockout (126), need to be better
understood, as does their relationship to the ApoEe4 phe-
notype. Also, it will be important to determine how the role
of insulin in glial cells can modify the effects of insulin on
appetite, energy balance, systemic metabolism, and brain
function. Ultimately, we want to know whether insulin ac-
tion in the brain may also be a potential therapeutic site for
mood disorders in the diabetic and/or nondiabetic popula-
tions. It is hoped that continued investigation of the mech-
anisms of insulin action in the brain in conjunction with
ongoing clinical trials will answer these questions.
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